Fresh off the $1.25 billion Flexus sale, Terry Rosen is aiming to build a major immuno-oncology biopharma from the ground up with upstart Arcus Biosciences.

CTI BioPharma), still under a clinical hold enforced by the FDA back in February for its investigational JAK2 inhibitor candidate pacritinib, has posted new…

Since Celyad failed to reach its primary endpoints in a stem cell therapy test in heart patients back in June, CardioCell has felt the pressure to deliver and…

TG Therapeutics got orphan drug designation from the FDA for both its clinical candidates this week.

Medivation loses its VP after the Pfizer buy, Shanghai Pharma loses its chairman after only three months and Sarah Jessica Parker waves goodbye to Mylan…

Belgium biotech argenx has seen its income double on the back of a strong year of deals, but has also seen fit to cut two former R&D pacts.

Struggling microcap GenVec has again been warned that it will be taken off the lucrative and respected Nasdaq exchange if it doesn’t get itself out of the…

Adocia has cut loose its diabetic foot ulcer program after the drug failed a Phase III trial.